PharmaShots Weekly Snapshots (November 29 -December 03, 2021)
Published: Dec 3, 2021 | Tags: BMS, US, FDA, sBLA, Priority Review, Reblozyl, luspatercept-aamt, Non-Transfusion Dependent Beta Thalassemia
Published: Dec 3, 2021 | Tags: Acasti Pharma, GTX-104, PK Bridging Study, Subarachnoid Hemorrhage
Published: Dec 3, 2021 | Tags: Molecular Partners, University of Bern, MP0533, AML
Published: Dec 3, 2021 | Tags: Takeda, Livtencity, maribavir, Post-Transplant Cytomegalovirus, Infection, US
Published: Dec 3, 2021 | Tags: BeiGene, EUSA, NMPA, Approval, Sylvant, siltuximab, China, Idiopathic Multicentric Castleman Disease
Published: Dec 3, 2021 | Tags: Protagonist, Janssen, PN-235, P-II, Clinical Studies, Multiple Indications
Published: Dec 2, 2021 | Tags: ITM, Navigo, FAP-targeting Radionuclide Therapy, Solid Tumors
Published: Dec 2, 2021 | Tags: Merck, US, FDA, sBLA, Priority Review, Vaxneuvance, pneumococcal 15-valent conjugate vaccine, Invasive Pneumococcal Disease
Published: Dec 2, 2021 | Tags: UCB, Co-Development, Co-Commercialization, Novartis, UCB0599, Parkinson Disease
Published: Dec 2, 2021 | Tags: Janssen, Amgen, Darzalex Faspro, daratumumab, hyaluronidase-fihj, US, FDA, Approval, Multiple Myeloma
Published: Dec 2, 2021 | Tags: Amgen, Otezla, apremilast, P-III, DISCREET Study, Genital Psoriasis
Published: Dec 2, 2021 | Tags: Astellas, ~$1.6M, Dyno, AAV Gene Therapy, Vectors, Skeletal, Cardiac Muscle
Sage and Biogen Report One-Year Results of Zuranolone in the P-III (SHORELINE) Study for the MDD
Published: Dec 1, 2021 | Tags: Sage, Biogen, Zuranolone, P-III, SHORELINE, Study, MDD
Published: Dec 1, 2021 | Tags: Ascentage, Innovent, Olverembatinib, NMPA, Approval, Chronic Myeloid Leukemia
AbbVie Submits Application to the EMA for Skyrizi (risankizumab) to Treat Crohn's Disease
Published: Dec 1, 2021 | Tags: AbbVie, EMA, Skyrizi, risankizumab, Crohn's Disease
Published: Dec 1, 2021 | Tags: Pfizer, NiKang, Combination Therapies, Advanced Clear Cell Renal Cell Carcinoma
Published: Dec 1, 2021 | Tags: Jazz, P-III, IMforte Trial, Zepzelca, lurbinectedin, Tecentriq, Extensive-Stage Small Cell Lung Cancer
Synaffix Expands the License Agreement with Mersana to Develop ADCs Targeting Cancers for ~$1B
Published: Dec 1, 2021 | Tags: Synaffix, Mersana, ADCs, Cancers, ~$1B
Published: Nov 30, 2021 | Tags: Taiho, Arcus, Domvanalimab, AB308, NSCLC, Japan
Published: Nov 30, 2021 | Tags: AstraZeneca, Genetron Health, NGS-based MRD Assay, Solid Tumors, China
Published: Nov 30, 2021 | Tags: Junshi, Toripalimab, NMPA, Approval, Nasopharyngeal Carcinoma
Published: Nov 30, 2021 | Tags: Merck, Eisai, Keytruda, pembrolizumab, Lenvima, Lenvatinib, EC, Approval, Advanced Renal Cell Carcinoma
BMS Reports the US FDA Acceptance of NDA for Deucravacitinib to Treat Plaque Psoriasis
Published: Nov 30, 2021 | Tags: BMS, US, FDA, Acceptance, NDA, Deucravacitinib, Plaque Psoriasis
Blueprint Medicines to Acquire Lengo for ~$250M
Published: Nov 30, 2021 | Tags: Blueprint Medicines, Acquire, Lengo, ~$250M
Published: Nov 29, 2021 | Tags: SpringWorks, P-IIb, ReNeu Trial, Mirdametinib, NF1-Associated Plexiform Neurofibromas
Published: Nov 29, 2021 | Tags: Turnstone Biologics, Moffitt Cancer Center, TIL Immunotherapies, Solid Tumor
Published: Nov 29, 2021 | Tags: Qiagen, DiaSorin, QuantiFERON-TB Gold Plus Assay, US, FDA, Approval, Latent Tuberculosis
Published: Nov 29, 2021 | Tags: US, FDA, Ocugen, IND, Application, Covaxin, BBV152, COVID-19
Published: Nov 29, 2021 | Tags: Clover, P-II, Trial, COVID-19 Vaccine, COVID-19
Merck and Ridgeback Provide Update on MOVe-OUT Study of Molnupiravir for the Treatment of COVID-19
Published: Nov 29, 2021 | Tags: Merck, Ridgeback, MOVe-OUT, Study, Molnupiravir, COVID-19
Related Post: PharmaShots Weekly Snapshots (November 22-26, 2021)
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com